switching from liraglutide to semaglutide Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance Switching from Semaglutide to Tirzepatide

doi: 10.1159/000493965

Some are also approved for a liver condition known as metabolic dysfunction-associated steatohepatitis (MASH)

The rationale for blending these two peptides stems from their non-overlapping receptor targets and complementary metabolic effects: Amylin Pathway (Cagrilintide): Targets amylin receptors in the brainstem Creates meal-specific satiety signals Slows gastric emptying through distinct mechanisms Reduces meal size and eating frequency Triple Agonist Pathway (Retatrutide): Activates GIP, GLP-1, and glucagon receptors Enhances insulin secretion and glucose metabolism Increases energy expenditure through glucagon effects Provides broader metabolic regulation When combined, these pathways could theoretically provide additive or synergistic effects on weight management and metabolic function

FDA Adverse Event Reporting System (FAERS) Public Dashboard

Medical History Individuals with a history of arthritis or joint-related issues, such as rheumatoid arthritis, gout, or lupus, may be more susceptible to joint pain with semaglutide

(2024, February 19)